Detalhe da pesquisa
1.
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients less than 60 years of age: a prospective phase II study
Haematologica
; 2023 11 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37941409
2.
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
Eur J Haematol
; 103(3): 255-267, 2019 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-31231828
3.
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Br J Haematol
; 179(4): 586-597, 2017 11.
Artigo
Inglês
| MEDLINE | ID: mdl-28961309
4.
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Ann Hematol
; 96(11): 1857-1866, 2017 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-28905189
5.
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.
Acta Haematol
; 137(3): 163-172, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28399522
6.
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
N Engl J Med
; 366(19): 1759-69, 2012 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-22571200
7.
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Haematologica
; 98(5): 784-8, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-23242595
8.
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Blood
; 116(19): 3743-50, 2010 Nov 11.
Artigo
Inglês
| MEDLINE | ID: mdl-20628153
9.
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Haematologica
; 97(5): 784-91, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22133776
10.
POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience.
Ann Hematol
; 91(9): 1419-25, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22543828
11.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Lancet Oncol
; 12(5): 431-40, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21507715
12.
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
Br J Haematol
; 153(2): 212-21, 2011 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-21375521
13.
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Oncologist
; 16(4): 388-403, 2011.
Artigo
Inglês
| MEDLINE | ID: mdl-21441574
14.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med
; 359(9): 906-17, 2008 Aug 28.
Artigo
Inglês
| MEDLINE | ID: mdl-18753647
15.
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Eur J Haematol
; 86(1): 23-31, 2011 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-20874823
16.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Eur J Haematol
; 86(5): 372-84, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21366694
17.
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Lancet Oncol
; 11(11): 1086-95, 2010 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-20932799
18.
One CGIAR and the Integrated Agri-food Systems Initiative: From short-termism to transformation of the world's food systems.
PLoS One
; 16(6): e0252832, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34086831
19.
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Oncologist
; 15(1): 6-25, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-20086168
20.
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.
Haematologica
; 100(8): e328-30, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-25840600